Doxorubicin cardiomyopathy carries an approximately 50% mortality once congestive heart failure develops, with no effective treatments currently available.
Answers are grounded in this paper and cite their sources.
High mortality once HF develops in doxorubicin cardiomyopathy warrants close surveillance; leaves open need for effective therapies.
Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.
No takes yet. Share an insight, caveat, or question.
Chatterjee et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: